Literature DB >> 35083494

Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.

Joséphine Franceschi1, Marine Ehret, Laetitia Visseaux, Anne Durlach, Coralie Barbe, Éric Durot, Florent Grange.   

Abstract

Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥  2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/ Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16-101 months.

Entities:  

Mesh:

Year:  2022        PMID: 35083494      PMCID: PMC9558323          DOI: 10.2340/actadv.v102.1087

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  22 in total

1.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.

Authors:  H S Zackheim; S Amin; M Kashani-Sabet; A McMillan
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

2.  Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients.

Authors:  J-D Bouaziz; S Bastuji-Garin; E Poszepczynska-Guigné; J Wechsler; M Bagot
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

3.  [Cutaneous lymphoproliferations: proposal for the use of diagnostic algorithms based on 2760 cases of cutaneous lymphoproliferations taken from the INCa networks (LYMPHOPATH and GFELC) over a two-year period].

Authors:  Émilie Laban; Marie Beylot-Barry; Nicolas Ortonne; Maxime Battistella; Agnes Carlotti; Anne de Muret; Janine Wechsler; Brigitte Balme; Tony Petrella; Laurence Lamant; Éric Frouin; Jean-Philippe Merlio; Béatrice Vergier
Journal:  Ann Pathol       Date:  2015-03-13       Impact factor: 0.407

4.  Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.

Authors:  Hasan H Danish; Shuling Liu; Jaymin Jhaveri; Christopher R Flowers; Mary J Lechowicz; Natia Esiashvili; Mohammad K Khan
Journal:  Leuk Lymphoma       Date:  2016-04-22

5.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

6.  Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.

Authors:  F Grange; G Hedelin; P Joly; M Beylot-Barry; M D'Incan; M Delaunay; L Vaillant; M F Avril; J Bosq; J Wechsler; S Dalac; C Grosieux; N Franck; E Esteve; C Michel; C Bodemer; B Vergier; L Laroche; M Bagot
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

7.  Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

Authors:  F D Groves; M S Linet; L B Travis; S S Devesa
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

8.  Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study.

Authors:  K E Salhany; J B Cousar; J P Greer; T T Casey; J P Fields; R D Collins
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

9.  Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

Authors:  Rakhshandra Talpur; Staci Ward; Narin Apisarnthanarax; Joan Breuer-Mcham; Madeleine Duvic
Journal:  J Am Acad Dermatol       Date:  2002-11       Impact factor: 11.527

10.  Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Authors:  Rakhshandra Talpur; Lotika Singh; Seema Daulat; Ping Liu; Sarah Seyfer; Tanya Trynosky; Wei Wei; Madeleine Duvic
Journal:  Clin Cancer Res       Date:  2012-07-31       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.